End-of-day quote
Shenzhen S.E.
18:00:00 2024-06-25 EDT
5-day change
1st Jan Change
9.83
CNY
+1.76%
-5.84%
-32.02%
Hvsen Biotechnology Co., Ltd.'s Equity Buyback announced on April 22, 2022, has expired with 2,389,050 shares, representing 1.44% for CNY 50.02 million.
The company expired its plan on April 21, 2023.
Hvsen Biotechnology Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 29 May 2024
05-22
CI
Hvsen Biotechnology Co., Ltd. Proposes Final Cash Dividend for 2023
04-24
CI
Hvsen Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
04-24
CI
Hvsen Biotechnology Co., Ltd. announced a financing transaction
04-02
CI
Tech-Bank Food Co., Ltd. announced that it has received CNY 1.197979975 billion in funding from a group of investors
12-28
CI
Hvsen Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
23-10-29
CI
Hvsen Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
23-08-28
CI
Certain A Shares of Hvsen Biotechnology Co., Ltd. are subject to a Lock-Up Agreement Ending on 24-AUG-2023.
23-08-23
CI
Hvsen Biotechnology Co., Ltd. Implements Cash Dividend of A Shares for 2022, Payable on 21 June 2023
23-06-15
CI
Hvsen Biotechnology Co., Ltd. Approves Cash Dividend for the Year 2022
23-05-18
CI
Hvsen Biotechnology Co., Ltd. Proposes Final Cash Dividend for the Year 2022
23-04-27
CI
Hvsen Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-04-26
CI
Hvsen Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
23-04-26
CI
Tranche Update on Hvsen Biotechnology Co., Ltd.'s Equity Buyback Plan announced on April 22, 2022.
23-04-25
CI
Hvsen Biotechnology Co., Ltd.'s Equity Buyback announced on April 22, 2022, has expired with 2,389,050 shares, representing 1.44% for CNY 50.02 million.
23-04-20
CI
Tranche Update on Hvsen Biotechnology Co., Ltd.'s Equity Buyback Plan announced on April 22, 2022.
23-04-03
CI
Tranche Update on Hvsen Biotechnology Co., Ltd.'s Equity Buyback Plan announced on April 22, 2022.
23-01-03
CI
Hvsen Biotechnology Co., Ltd. Approves Board Appointments
22-12-12
CI
Hvsen Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
22-10-25
CI
Hubei Huisheng Biotechnology Co., Ltd. announced that it expects to receive CNY 700 million in funding from Hvsen Biotechnology Co., Ltd.
22-10-24
CI
Tranche Update on Hvsen Biotechnology Co., Ltd.'s Equity Buyback Plan announced on April 22, 2022.
22-10-09
CI
Hvsen Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
22-08-29
CI
Certain A Shares of Hvsen Biotechnology Co., Ltd. are subject to a Lock-Up Agreement Ending on 24-AUG-2022.
22-08-23
CI
Tranche Update on Hvsen Biotechnology Co., Ltd.'s Equity Buyback Plan announced on April 22, 2022.
22-07-01
CI
Hvsen Biotechnology Co., Ltd. announces an Equity Buyback for CNY 100 million worth of its shares.
22-04-22
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Wuhan Hvsen Biotechnology Co Ltd is a China-based company mainly engaged in the research, development, production and sales of veterinary drugs, feed and additives. The Companyâs main products include veterinary active pharmaceutical ingredients, veterinary chemical preparations, veterinary traditional Chinese medicine preparations, feed and additives and environmental improvers, such as tyvanicin tartrate, florfenicol powder, banqing granules and piglet composites pre-mixed feed, etc. The Company mainly conducts its businesses in the China market.
More about the company
1st Jan change
Capi.
-32.02% 217M -14.11% 76.65B +20.03% 8.82B +22.25% 3.6B +14.02% 1.65B -7.03% 1.22B -30.92% 1.11B -34.32% 1.08B -25.17% 948M -1.90% 936M
Veterinary Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1